Biodexa Pharmaceuticals Stock Forecast

Stock Price Forecast

There have not been any analyst price target forecasts for Biodexa Pharmaceuticals in the last 12 months.

Price Target: n/a

Analyst Consensus: n/a

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

There are currently no analyst ratings available for Biodexa Pharmaceuticals.

Recommendation Trends

Rating	Feb '24
Strong Buy	0
Buy	0
Hold	0
Sell	0
Strong Sell	0
Total	0

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Aydin Huseynov Ladenburg Thalmann	Ladenburg Thalmann	Strong Buy Initiates $10,000	Strong Buy	Initiates	$10,000	+298,407.46%	Feb 8, 2024

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

3.07K

EPS This Year

-2.94

from -58.18

EPS Next Year

-2.30

from -2.94

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	578.00K	699.00K	381.00K	-	-	-	3.07K
Revenue Growth	68.51%	20.93%	-45.49%	-	-	-	-
EPS	-	-	-	-	-58.18	-2.94	-2.30
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	3	3

Financial currency is GBP. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	n/a	3,157
Avg	n/a	3,067
Low	n/a	2,947

Revenue Growth

Revenue Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2026	2027
High	-3.03	-2.37
Avg	-2.94	-2.30
Low	-2.82	-2.21

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.